Compare FUL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | ARQT |
|---|---|---|
| Founded | 1887 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | FUL | ARQT |
|---|---|---|
| Price | $63.38 | $30.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $68.50 | $24.83 |
| AVG Volume (30 Days) | 341.4K | ★ 1.8M |
| Earning Date | 01-14-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $3,502,085,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | $1.91 | $30.74 |
| P/E Ratio | $29.57 | ★ N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $47.56 | $11.13 |
| 52 Week High | $65.36 | $31.77 |
| Indicator | FUL | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 65.91 | 57.63 |
| Support Level | $59.36 | $28.75 |
| Resistance Level | $62.00 | $30.60 |
| Average True Range (ATR) | 1.36 | 1.22 |
| MACD | 0.16 | -0.04 |
| Stochastic Oscillator | 94.58 | 82.16 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.